Abstract
Growth factors are proteins that work as paracrine or au-tocrine modulators of cell proliferation. Many growth factors have been isolated that were originally purified on the basis of a specific biological effect and subsequently named for this effect. Once the factor was isolated to homogeneity, the amino acid sequence was determined and recombinant proteins developed. Upon testing of recombinant proteins in a variety of systems it was found that many factors not only have overlapping functions but also act on a wide range of cell types to produce a variety of actions. In addition to the effects of individual factors on cells involved in the wound healing process, many of these factors interact with other substances to antagonize or synergize their effects, perhaps through the use of similar second-messenger systems or modulation of receptor-ligand affinity. The susceptibility of tissues to modulation by growth factors may change as wound healing progresses.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Abe H, Rodgers KE, Ellefson D, diZerega GS. (1991). Kinetics of interleukin-1 and tumor necrosis factor secretion by rabbit macrophages recovered from the peritoneal cavity after surgery. J Invest Surg. 4: 141–1.
Abraham RT, Ho SN, Barna TJ, McKean DJ. (1987). Transmembrane signaling during interleukin-1 dependent T cell activation. Interactions of signal 1-and 2-type mediators with the phosphoinositide-dependent signal transduction mechanism. J Biol Chem. 262: 2719–2728.
Adashi EY, Resnick CE, Bergeman CS, Gospodarowicz D. (1987). Fibroblast growth factor as a regulator of ovarian granulosa cell differentiation: a novel non-mitogenic role. J Biol Chem. 262: 1–13.
Aggarwal BB, Eessalu TE, Hass PE. (1985). Characterization of receptors for human tumor necrosis factor and their regulation by 7-interferon. Nature. 318: 665–667.
Akahoshi T, Oppenheim J J, Matsushima K. (1988). Interleukin-1 stimulatesits own receptor expression on human fibroblasts through the endogenous production of prostaglandins. J Clin Invest. 82: 1219–1224.
Alexander RB, Nelson WG, Coffey DS. (1987). Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drug targeted at DNA topoisomerase II. Cancer Res. 47: 2403–2406.
Anzano MA, Roberts AB, Sporn MB. (1986). Anchorage-independent growth of primary rat embryo cells in induced by platelet-derived growth factor and inhibited by type-beta transforming growth factor. J Cell Physiol. 126: 312–318.
Arend WP, D’Angelo S, Massoni RJ, Joslin FG. (1985a). Interleukin-1 production by human monocytes: effects of different stimuli. In: Kluger MJ, Oppenheim JJ, Powanda MX, eds. The Physiologic, Metabolic and Immunologic Actions of Interleukin. New York: Alan Liss; 399–426.
Arend WP, Joslin FG, Massoni RJ. (1985b). Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol. 134: 3868–3875.
Arend WP, Gordon DF, Wood WM, Janson RW, Joslin FG, Jameel S. (1989). IL-13 production in cultured human monocytes is regulated at multiple levels. J Immunol. 143: 118–126.
Arenzana-Seisdedos F, Virelizier J-L. (1983). Interferons as macrophage activating factors. II. Enhanced secretion of interleukin-1 by lipopolysaccharide-stimulated human monocytes. Eur J Immunol. 13: 437–440.
Armelin HA, Armelin MCS, Kelly K, Stewart T, Leder P, Cochran BH, Stiles CD. (1984). Functional role of c myc in mitogenic response to platelet derived growth factor precedes activation of c myc. Nature. 310: 655–660.
Arturson G. (1984). Epidermal growth factor in the healing of corneal wounds, epidermal wounds and partial thickness scalds. Scand J Plast Reconstr Surg. 18: 33–37.
Assoian RK, Komoriya K, Meyers CA, Miller DM, Sporn MB. (1983). Transforming growth factor-β in human platelets. Identification of a major storage site, purification and characterization. J Biol Chem. 258: 7155–7160.
Assoian RK, Frolik CA, Roberts AB, Miller DM, Sporn MB. (1984). Transforming growth factor beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell. 36: 35–41.
Assoian RK, Sporn MB. (1986). Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol. 142: 1217–1223.
Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB. (1987). Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA. 84: 1681–1687.
Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA. (1984). Nucleotide sequence of human monocyte interleukin-1 precursor cDNA. Proc Natl Acad Sci USA. 81: 7907–7911.
Auron PE, Warner SJ, Webb AC, Cannon JG, Bernheim HA, McAdam KJP, Rosenwasser LJ, LoPreste G, Mucci SF, Dinarello CA. (1987). Studies on the molecular nature of interleukin-1. J Immunol. 138: 1447–1456.
Bachelet M, Masliah J, Vargaftig BB, Bereziat G, Colard O. (1986). Changes induced by PAF-acether in diacyl and ether phospholipids from guinea-pig alveolar macrophages. Biochim Biophys Acta. 878: 177–183.
Bagby GC, Dinarello CA, Wallace P, Wagner C, Hefeneider S, McCall E. (1986). Interleukin-1 stimulates granulocyte macrophage colony stimulating activity release by vascular endothelial cells. J Clin Invest. 78: 1316–1323.
Baglioni C, McCandless S, Tavernier J, Fiers W. (1985). Binding of human tumor necrosis factor to high affinity receptors on HELA and lymphoblastoid cells sensitive to growth inhibition. J Biol Chem. 260: 13395–13397.
Baird A, Durkin T. (1986). Inhibition of endothelial cell proliferation by type-beta transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun. 138: 476–482.
Baird A, Esch F, Mormede P, Ueno N, Ling N, Bohlen P, Ying SY, Wehrenberg WB, Guillemin R. (1986). Molecular characterization of fibroblast growth factor: distribution and biological activities in various tissues. Recent Prog Horm Res. 42: 143–205.
Bakouche O, Ichinose Y, Heicappell R, Fidler IJ, Lachman LB. (1988). Plasma membrane associated tumor necrosis factor: a non-integral membrane protein possibly bound to its own recepter. J Immunol. 142: 1142–1147.
Balavoine JF, de Rochemonteix B, Williamson K, Sekinger P, Cruchaud A, Dayer J-M. (1986). Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin-1 and inhibitors). J Clin Invest. 78: 1120–1124.
Barak V, Treves AJ, Yanai P, Halperin M, Wasserman D, Birin S, Brown S. (1986). Interleukin-1 inhibitory activity secreted by a human myelomonocytic cell line (C20). Eur J Immunol. 16: 1449–1452.
Barrett TB, Gajdusek CM, Schwartz SM, McDougall JK, Benditt EP. (1984). Expression of the sis gene by endothelial cells in culture and in vivo. Proc Natl Acad Sci USA. 81: 6772–6774.
Beck G, Habicht GS, Benach JL, Miller F. (1986). Interleukin-1: a common endogenous mediator of inflammation and the local Shwartzman reaction. J Immunol. 136: 3025–3031.
Berk BC, Alexander RW, Brock TA, Gimbrone MA, Webb CR. (1986). Vaso-constriction: a new activity for platelet-derived growth factor. Science. 232: 87–90.
Berman MA, SandbergCI, Calabia BS, Andrews BS, Friou GJ. (1987). Interleukin-1 inhibitor masks high interleukin-1 production in acquired immune deficiency syndrome (AIDS). Clin Immunol Immunopathol. 42: 133–140.
Bernheim HA, Dinarello CA. (1985). Effects of purified human interleukin-1 on the release of prostaglandin E2 from fibroblasts. Br J Rheumatol. 24: 122–127.
Bernton EW, Beach JE, Holaday JW, Smallbridge RC, Fein HG. (1987). Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science. 238: 519–521.
Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. (1986). Stim-ulation of bone marrow resorption and inhibition of bone marrow formation in vitro by human tumor necrosis factors. Nature. 319: 516–519.
Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitck R, Cerami A. (1985a). Identity of tumor necrosis factor and the macrophage secreted factor cachectin. Nature. 316: 552–554.
Beutler B, Mahoney J, LeTrang N, Pekala P, Cerami A. (1985b). Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-in-duced RAW 264.7 cells. J Exp Med. 161: 984–995.
Beutler B, Cerami A. (1986). Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature. 320: 584–588.
Beutler B, Tkacenko V, Milsark I, Krockin N, Cerami A. (1986). Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of lpsd (endotoxin resistance) phenotype. J Exp Med. 164: 1791–1796.
Bevilacqua MP, Pober JS, Majeau GR, Contran RA, Gimbrone MA. (1984). Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of pro-coagulant activity in human vascular endothelial cells. J Exp Med. 160: 618–623.
Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. (1985). In-terleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte lines. J Clin Invest. 76: 2003–2007.
Bevilacqua MP, Schleef RR, Gimbrone MA, Loskutoff DJ. (1986a). Regulation of the fibrinolytic system of cultures of human endothelium by interleukin-1. J Clin Invest. 78: 587–591.
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA. (1986b). Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA. 83: 4533–4537.
Bird TA, Saklatvala J. (1987). Studies on the fate of receptor-bound 1251-inter-leukin 1/3 in porcine synovial fibroblasts. J Immunol. 139: 92–97.
Black RA, Kronheim SR, Cantrell M, Deeley MC, March CJ, Prickett KS, Wignall J, Conlon PJ, Cosman D, Hopp TP, Mochizuki DY. (1988). Generation of biologically active interleukin-1β by proteolytic cleavage of the inactive precursor. J Biol Chem. 263: 9437–9442.
Bohlen P, Esch F, Baird A, Gospodarowicz D. (1985). Acidic fibroblast growth factor from bovine brain. Amino terminal sequence and comparison to basic fibroblast growth factor. EMBO J. 4: 1951–1956.
Bonin PD, Singh JP. (1988). Modulation of interleukin-1 receptor expression and interleukin-1 response in fibroblasts by platelet-derived growth factor. J Biol Chem. 263: 11052–11055.
Bonney RJ, Humes JL. (1984). Physiological and pharmalogical regulation of prostaglandin and leukotriene production by macrophages. J Leukocyte Biol. 35: 1–10.
Boraschi D, Tagliabue A. (1984). Multiple modulation of macrophage functions by lymphokines: different effects of interferon and macrophage activating factor. In: Pick E, ed. Lyymphokines. San Diego: Academic Press; 9: 71–99.
Bowen-Pope DF, Ross R. (1985). Methods for studying the platelet-derived growth factor receptors. Methods. Enzymology. 109: 69–100.
Bron C, MacDonald HR. (1987). Identification of a plasma membrane receptor for interleukin-1 on mouse thymoma cells FEBS Lett. 219: 365–368.
Bronson RE, Bentilami CN, Siebert EP. (1987). Modulation of fibroblast growth and glycosaminoglycan synthesis by interleukin-1. Coll Relat Res. 7: 323–332.
Broudy VC, Kaushansky K, Harlan JM, Adamson JW. (1987). Interleukin-1 stimulates endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony stimulating factor. J Immunol. 139: 464–468.
Brown GL, Curtsinger, LJ III, Brightwell JR, Ackerman DM, Polk HE, Schultz GS. (1985). Human epidermal growth factor accelerates epithelialization of partial-thickness burns (abstract). Presented at the Association for Academic Surgery 19th Annual Meeting, p. 67.
Brown GL, Curtsinger L III, Brightwell JR, Ackerman DM, Tobin GR, Polk HC Jr, George-Nascimento C, Valenzuela P, Schultz GS. (1986). Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med. 163: 1319–1324.
Brown GL, Curtsinger LJ III, White M, Mitchell RO, Pietsch J, Nordquest R, von Fraunhofer A, Schultz GS. (1988). Acceleration of tensile strength of incisions treated with EGF and TGF-0. Ann Surg. 208: 788–794.
Brown GL, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curtsinger LJ III, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. (1989). Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med. 321: 76–79.
Brown K. (1986). Uromodulin, an immunosuppressive protein derived from pregnancy urine, is an inhibitor of interleukin-1. Proc Natl Acad Sci USA. 83: 9119–9123.
Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, Hoffman R, Rubin BY. (1986). The suppressive influences of human tumor necrosis factor on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol. 136: 4487–4495.
Bucher NLR. (1978). Hormonal factors and liver growth. Adv Enzyme Regul. 16: 205–215.
Buckley A, Davidson JM, Kamerath CD, Wolt TB, Woodward SC. (1985). Sus-tained release of epidermal growth factor accelerates wound repair. Proc Natl Acad Sci USA. 82: 7340–7344.
Bunning RA, Crawford A, Richardson HJ, Openakker G, Van Damme J, Russell RG. (1987). Interleukin-1 preferentially stimulates the production of tissue type plasminogen activator by human articular chondrocytes. Biochim Biophys Acta. 924: 473–482.
Burchett SK, Weaver WM, Westall JA, Larsen A, Kronheim S, Wilson CB. (1988). Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol. 140: 3473–3481.
Canalis R. (1986). Interleukin-1 has independent effects on DNA and collagen synthesis in cultures of rat calvariae. Endocrinology. 118: 74–81.
Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. (1986). Identification of a common nucleotide sequence in the 3’ untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA. 83: 1670–1674.
Carpenter G, Cohen S. (1976a). 125I-labeled human epidermal growth factor (hEGF): binding, internalization and degradation in human fibroblasts. J Cell Biol. 71: 159–171.
Carpenter G, Cohen S. (1976b). Human epidermal growth factor and the proliferation of human fibroblasts. J Cell Physiol. 88: 227–237.
Carpenter G, Cohen S. (1979). Epidermal growth factor. Annu Rev Biochem. 48: 193–216.
Carpenter G, King L, Cohen S. (1979). Epidermal growth factor-receptor-protein kinase interactions. J Biol Chem. 255: 4834–4842.
Carpenter G. (1985). Epidermal growth factor: biology and receptor metabolism. J Cell Sci Suppl. 3: 1–9.
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 72: 3666–3670.
Carter DM, Balin AK, Gottliet AB, Eisenger M, Lin A, Pratt L, Sherbany A, Caldwell D. (1988). Clinical experience with crude preparation of growth factors in healing of chronic wounds in human subjects. In: Arbul A, Pines E, Caldwell M, Hunt TK, eds. Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Research. New York: Alan Liss; 266: 303–317.
Catterton WZ, Escobedo MB, Sexson WR, Gray ME, Sundell HW, Stahlman MT. (1979). The effects of epidermal growth factor on lung maturation in fetal rabbit. Pediatr Res. 13: 104–108.
Cavender DE, Haskard DO, Joseph B, Ziff M. (1986). Interleukin-1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J Immunol 136: 203–207.
Centrella M, McCarthy TL, Canalis E. (1987). Transforming growth factor beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J Biol Chem. 262: 2869–2874.
Chantry D, Turner M, Feldman M. (1988). Regulation of interleukin-1 and tumor necrosis factor mRNA and protein by transforming growth factor beta. Lymphokine Res. 7: 283–306.
Chapman HA, Stone OL. (1985). Characterization of macrophage derived plasminogen activator inhibitor (similarities with placental urokinase inhibitor). Biochem J. 230: 109–116.
Chegini N, Simms JS, Williams RS, Rossi AMK, Masterson BJ. (1991). Identification of transforming growth factors alpha and beta (TGF-α and TGF-β) in postoperative adhesion formation. 38th Annual Meeting for Society of Gynecological Investigation, San Antonio, TX, pp. 331.
Cheifetz S, Weatherbee JA, Tsang MLS, Anderson JIC, Mole JE, Lucas R, Massague J. (1987). The transforming growth factor-beta system, a complex pattern of cross-reactive legends and receptors. Cell. 48: 409–415.
Chen WS, Lazar CS, Poenie M, Tsien RY, Gill G, Rosenfeld MG. (1987). Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature. 328: 820–823.
Chiang C-P, Nilsen-Hamilton M. (1986). Opposite and selective effects of epidermal growth factor and human platelet transforming growth factor-beta on the production of secreted proteins by murine 3T3 cells and human fibroblasts. J Biol Chem. 261: 10478–10481.
Chinkers M, McKanna JA, Cohen S. (1979). Rapid induction of morphological changes in human carcinoma cells A-431 by epidermal growth factor. J Cell Biol. 83: 260–265.
Chuo P, Francis L, Atkins F. (1977). The release of an endogenous pyrogen from guinea pig leukocytes in vitro. A new model for investigating the role of lymphocytes in fevers induced by antigens in hosts with delayed hypersensitivity. J Exp Med. 145: 1288–1298.
Chvapil M, Gaines JA, Gilman T. (1988). Lanolin and epidermal growth factor in healing of partial thickness pig wounds. J Burn Care Rehabil. 9: 279–284.
Cohen S. (1962). Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem. 237: 1562–1568.
Cohen S, Elliott GA. (1963). The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse. J Invest Dermatol 40: 1–5.
Cohen S. (1965). The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol. 12: 394–407.
Cohen S, Taylor JM. (1974). Epidermal growth factor: chemical and biological characterization. Recent Prog Horm Res. 30: 533–550.
Coley WB. (1893). The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci. 105: 487–511.
Collins MKL, Sinnett-Smith JW, Rozengurt E. (1983). Platelet derived growth factor treatment decreases the affinity of the epidermal growth factor receptors of swiss 3T3 cells. J Biol Chem. 258: 11689–11693.
Collins T, Lapierre LA, Riers W, Strominger JL, Pober JS. (1986). Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA. 83: 446–450.
Conlon PJ, Grabstein KH, Alpert A, Prickett KS, Hopp TP, Gillis S. (1987). Localization of human mononuclear cell interleukin-1. J Immunol. 139: 98–102.
Cooper ML, Hansbrough JF, Foreman TJ, Sakabu SA, Laxer JA. (1991). The effects of epidermal growth factor and basic fibroblast growth factor on epithelialization of meshed skin graft interstices. In: Caldwell MD, Hunt TK, Pines E, Skovee G, eds. Clinical and Experimental Approaches to Dermal and Epidermal Repair Normal and Chronic Wounds. New York: Wiley-Liss; 365: 429–442.
Czarnetzki G. (1983). Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. Clin Exp Immunol. 54: 486–492.
Davidson J, Bulkley A, Woodward S, Nichols W, McGee G, Demerriou A. (1988). Mechanisms of accelerated wound repair using epidermal growth factor and basic fibroblast growth factor. In: Barbul A, Pines E, Caldwell M, Hunt TK, eds. Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Research. New York: Alan R. Liss; 266: 63–75.
Davis L, Lipsky PE. (1986). Signals involved in T cell activation. II. Distinct roles of intact accessory cells, phorbol esters, and interleukin-1 in activation and cell cycle progression of resting T lymphocytes. J Immunol. 136: 3588–3596.
Dayer J-M, Beutler B, Cerami A. (1985). Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 162: 2163–2168.
Decker SJ, Harris P. (1989). Effects of platelet-derived growth factor on phosphorylation of the epidermal growth factor receptor in human skin fibroblasts. J Biol Chem. 264: 9204–9209.
Degliantoni G, Murphy M, Kobayashi M, Francis MK, Perussia B, Trinchieri G. (1985). Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor: relationship with tumor necrosis factor and synergism with immune interferon. J Exp Med. 162: 1512–1530.
Dejana E, Brevario F, Erroi A, Bussolino F, Mussoni L, Gramse M, Pintucci G, Casali B, Dinarello CA, Van Damme J, Mantovani A. (1987). Modulation of endothelial cell function by different molecular species of interleukin-1. Blood. 69: 695–699.
Dejana E, Bertocchi F, Bortolami MC, Regonesi A, Tonta A, Breviario F, Giavazzi R. (1988). Interleukin-1 promotes tumor cell adhesion to cultured human endothelial cells. J Clin Invest. 82: 1466–1470.
DeLarco JE, Todaro GJ. (1978). Growth factors from murine sarcoma virus transformed cells. Proc Natl Acad Sci USA. 75: 4001–4005.
Demczuk S, Baumberger C, Mach B, Dayer J-M. (1987). Expression of human IL-1α and β messenger RNAs and IL-1 activity in human peripheral blood mononuclear cells. J Mol Cell Immunol. 3: 255–265.
Demopoulos CA, Pinckard RN, Hanahan DJ. (1979). Platelet-activating factor. Evidence for 1-0-alkylA-2acetyl-sn-glyceryl-α-1-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 254: 9355–9358.
Derynck R, Roberts AB, Winkler ME, Chen EY, Goeddel DV. (1984). Human transforming growth factor-i: precursor structure and expression in E. coli. Cell. 38: 287–297.
Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. (1985). Human transforming factor beta cDNA sequence and expression in tumor cell lines. Nature. 316: 701–705.
Deuel TF, Huang JS. (1983). Platelet-derived growth factor: purification, properties, and biological activities. Prog Hematol. 13: 201–221.
Deuel TF. (1987). Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol. 3: 443–492.
DiCorleto PE, Bowen-Pope DF. (1983). Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA. 80: 1919–1923.
Dinarello CA, Renfer L, Wolff SM. (1977). Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci USA. 74: 4624–4627.
Dinarello CA. (1985). The physiologic, metabolic, and immunologic actions of interleukin-1. In: Kluger MJ, Oppenheim JJ, Powanda MC, eds. Biology of Interleukin-1. New York: Alan R. Liss; 1–19.
Dinarello CA, Cannon JG, Mier JW, Bernheim HA, LoPreste G, Lynn DL, Love RN, Webb AC, Auron PE, Reuben RC, Rich A, Wolff SM, Putney SD. (1986a). Multiple biological activities of human recombinant interleukin-1. J Clin Invest. 77: 1734–1739.
Dinarello CA, Cannon JG, Wolff SM. (1986b). Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med. 163: 1443–1450.
Doolittle RF, Hunkapiller MW, Hood LE, Devare SG, Robbins K, Aaronson SA, Antoniades HN. (1983). Simian sarcoma virus one gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science. 221: 275–277.
Dower SK, Kronheim SR, March CJ, Conlon PJ, Hopp TP, Gillis S, Urdal DL. (1985). Detection and characterization of high affinity receptors for human interleukin-1. J Exp Med. 162: 501–515.
Dower SK, Urdal DL. (1987). The interleukin-1 receptor. Immunol Today. 8: 46–51.
Duff GW, Forre O, Waalen K, Dickens SE, Kvamesh L, Nuki G. (1985). Interleukin-1 activity produced by human rheumatoid and normal dendritic cells. Br J Rheumatol. 24: 94–98.
Durum SK, Higuchi C, Ron Y. (1984). High affinity interleukin-1 receptors. Immunobiology. 168: 213–231.
Eisinger M, Sadan S, Soehnchen R, Silver IA. (1988). Wound healing by epider-mal-derived factors: experimental and preliminary clinical studies. In: Dicken SF, Kvarmes L, Nuko G, eds. Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Research. New York: Alan R. Liss; 266: 291–302.
Ek B, Westermark B, Wasteson A, Heldin C-H. (1982). Stimulation of tyrosine-specific phosphorylation by platelet-derived growth factor. Nature. 295: 419–420.
Elias JA, Gustilo K, Baeder W, Freundlich B. (1987). Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin-1 and tumor necrosis factor. J Immunol. 138: 3812–3816.
Elias L, Moore PB, Rose SM. (1988). Tumor necrosis factor induced DNA fragmentation of HL-60 cells. Biochem Biophys Res Commun. 157: 963–969.
Emeis JJ, Kooestra J. (1986). Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med. 163: 1260–1266.
Engrav LH, Richey KJ, Kao CC, Murray MJ. (1989). Topical growth factors and wound contraction in the rat: Part II. Platelet-derived growth factor and wound contraction in normal and steroid-impaired rats. Ann Plast Surg. 23: 245–248.
Esch F, Baird A, Ling N, Ueno N, Hill F, Deneroy L, Klepper R, Gospodarowicz D, Bohlen P, Guillemin R. (1985). Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA. 85: 6507–6511.
Estes JE, Pledger WJ, Gillespie GY. (1984). Macrophage derived growth factor for fibroblasts and interleukin-1 are distinct entities. J Leukoc Biol. 35: 115–129.
Fanger BO, Wakefield LM, Sporn MB. (1986). Structure and properties of the cellular receptor for transforming growth factor type beta. Biochemistry. 25: 3083–3091.
Farr AG, Dorf ME, Unanue ER. (1977). Secretion of mediators following T lymphocyte-macrophage interaction is regulated by the major histocompatability complex. Proc Natl Acad Sci USA. 74: 3542–3546.
Fenton MJ, Clark BD, Collins KL, Webb AC, Rich A, PE Auron. (1987). Transcriptional regulation of the human prointerleukin 1β gene. J Immunol. 138: 3972–3979.
Fontana A, Kristinsen F, Pub R, Gemsa D, Weber E. (1982). Production of prostaglandin E and an interleukin-1 by cultured astrocytes and C6 glioma cells. J Immunol. 129: 2413–2419.
Fourtanier AY, Courty J, Muller E, Courtois Y, Prunieras M, Berritault D. (1986). Eye-derived growth factor isolated from bovine retina and used for epidermal wound healing in vivo. J Invest Dermatol. 87: 76–80.
Franklin JD, Lynch JB. (1979). Effects of topical applications of epidermal growth factor on wound healing. Plast Reconstr Surg. 64: 766–770.
Franklin TJ, Gregory H, Morris WP. (1986). Acceleration of wound healing by recombinant human urogastrone (epidermal growth factor). J Lab Clin Med. 108: 103–108.
Fransen L, Van Der Heyden J, Ruysschaert R, Fiers W. (1986). Recombinant tumor necrosis factor: its effect and its synergism with interferon-7 on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol. 22: 419–426.
Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB. (1983). Purification and initial characterization of a type fi transforming growth factor from human placenta. Proc Natl Acad Sci USA. 80: 3676–3680.
Fukasawa M, Yanagihara DL, Rodgers KE, diZerega GS. (1989). The mitogenic activity of peritoneal tissue repair cells: control by growth factor. J Surg Res. 47: 45–51.
Fukasawa M, Campeau JD, Yanigihara DL, Rodgers KE, diZerega GS. (1990). Regulation of proliferation of peritoneal tissue repair cells by peritoneal macrophages. J Surg Res. 49: 81–87.
Fulbrigge RC, Chaplin DD, Kiely J-M, Unanue ER. (1987). Regulation of interleukin-1 gene expression by adherence and lipopolysaccharide. J Immunol. 138: 3799–3802.
Furutani Y, Notake M, Yamayoshi M, Yamagishi J, Nomura H, Ohue M, Fukui T, Yamada M, Nakamura S. (1985). Cloning and characterization of cDNAs for human and rabbit interleukin-1 precursor. Nucleic Acids Res. 13: 5869–5882.
Gahring L, Baltz M, Pepys MB, Daynes R. (1984). Effect of ultraviolet radiation on production of epidermal cell thymocyte activating factor/interleukin-1 in vivo and in vitro. Proc Natl Acad Sci USA. 81: 1198–1202.
Gajusek C, Carbon S, Ross R, Nawroth P, Stern D. (1986). Activation of coagulation releases endothelial cell mitogens. J Cell Biol. 103: 419–428.
Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. (1985). Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA. 82: 8667–8771.
Gamble JR, Vadas MA. (1988). Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor beta. Science. 242: 97–99.
Gery I, Waksman BH. (1972). Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediators). J Exp Med. 136: 143–155.
Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, Dinarello CA. (1986). Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun. 54: 837–840.
Gilman SC, Rosenberg JS, Feldman JD. (1984). Immune complexes in endocarditis. J Immunol. 133: 217–221.
Giri I, Lepe-Zuniya JL. (1983). Lymphocyte activating factors. In: Pick EJ, ed. Lymphokines. San Diego: Academic Press: 9: 109–126.
Giri JG, Lomedico PT, Mizel SB. (1985). Studies on the synthesis and secretion of interleukin-1. I. A 33,000 molecular weight precursor for interleukin-1. J Immunol. 134: 343–349.
Goodson WH III, Hunt TK. (1977). Studies of wound healing in experimental diabetes mellutes. J Surg Res. 22: 221–227.
Gorden P, Carpentier JL, Cohen S, Orci L. (1978). Epidermal growth factor: morphological demonstration of binding, internalization and lysosomal asso-ciation in human fibroblasts. Proc Natl Acad Sci USA. 75: 5025–5029.
Gospodarowicz D. (1974). Localization of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature. 249: 123–127.
Gospodarowicz D, Moran JS. (1974). Effect of fibroblast growth factor, insulin, dexamethasone and serum on the morphology of BALB/c 3T3 cells. Proc Natl Acad Sci USA. 71: 4648–4652.
Gospodarowicz D, Moran JS. (1975). Mitogenic effect of fibroblast factor on early passage of human and murine fibroblasts. J Cell Biol. 66: 451–456.
Gospodarowicz D, Weseman F, Moran J. (1975). Presence in the brain of a mitogenic agent distinct from fibroblast growth factor that promotes the proliferation of myoblasts in low density in culture. Nature. 256: 216–219.
Gospodarowicz D, Bialecki H. (1978). The effects of the epidermal and fibroblast growth factor and the replicative lifespan of bovine granulosa cells in culture. Endocrinology. 103: 854–865.
Gospodarowicz D, Brown KS, Birdwell CR, Zetter B. (1978a). Control of proliferation of human vascular endothelial cells of human origin: I. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol. 77: 774–788.
Gospodarowicz D, Greenburg G, Bialecki H, Zetter B. (1978b). Factors involved in the modulation of cell proliferation in vivo and in vitro: the role of fibroblast and epidermal growth factors in the proliferative response of mammalian cells. In Vitro. 14: 85–118.
Gospodarowicz D, Mescher AL, Moran JS. (1978c). Cellular specificity of fibroblast growth factor and epidermal growth factor. In: Symposia of the Society for Developmental Biology. New York: Academic Press; 35: 33–61.
Gospodarowicz D, Vlodavsky I, Greenburg G, Alvarado J, Johnson LK, Moran J. (1979a). Cellular shape is determined by the extracellular matrix and is responsible for the control of cellular growth and function. Cold Spring Harbor Conference on Cell Proliferation 9: 561–592.
Gospodarowicz D, Tauber J-P. (1980). Growth factors and extracellular matrix. i. 1: 201–267.
Gospodarowicz D, Mescher AL. (1981). Fibroblast growth factor and vertebrate regeneration. Adv Neurol (Neurofibromatosis). 29: 149–171.
Gospodarowicz D, Vlodavsky I, Savion N. (1981). The role of fibroblast growth factor and the extracellular matrix in the control of proliferation and differentiation of corneal endothelial cells. Vision Res. 21: 87–103.
Gospodarowicz D. (1983a). Growth factors and their action in vivo and in vitro. J Pathol. 141: 201–233.
Gospodarowicz D. (1983b). The control of mammalian cell proliferation by growth factors, basement lamina and lipoproteins. J Invest Dermatol. 81: 405–503.
Gospodarowicz D. (1984). Fibroblast growth factor. In: Li CH, ed. Hormonal Proteins and Peptides. New York: Academic Press; 12: 205–230.
Gospodarowicz D, Cheng J, Lui G-M, Bohlen P. (1984). Isolation by heparin-sepharose affinity chromatography of brain fibroblast growth factor: identity with pituitary fibroblast growth factor. Proc Natl Acad Sci USA. 81: 6963–6967.
Gospodarowicz D. (1985). Biological activity in vivo and in vitro of pituitary and brain fibroblast growth factor. In: Ford RJ, Maizel AL, ed. Mediators in Cell Growth and Differentiation. New York: Raven Press; 109–134.
Gospodarowicz D, Massaglia S, Cheng J, Lui G-M, Bohlen P. (1985). Isolation of bovine pituitary fibroblast growth factor purified by fast protein liquid chromatography (FPLC). Partial chemical and biological characterization. J Cell Physiol. 122: 323–332.
Gospodarowicz D. (1986). Purification of brain and pituitary FGF. In: Barnes D, Sirbasku D, eds. Methods in Enzymology. New York: Academic Press; 147: 106–119.
Gospodarowicz D, Cheng J. (1986). Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128: 475–484.
Gospodarowicz D, Neufeld G, Schweigerer L. (1986). Fibroblast growth factor. Mol Cell Endocrinol 46: 187–204.
Goto K, Nakamura S, Goto F, Myoshinagu M. (1984). Generation of an interleukin 1—like lymphocyte stimulating factor at inflammatory sites: correlation with the infiltration of polymorphonuclear leukocytes. Br J Exp Pathol 65: 521–532.
Goustin AS, Betsholtz C, Pfeiffer-Ohlsson S, Persson H, Ryndert J. (1985). Coexpression of the sis and myc proto-oncogenes in developing human placenta suggests autocrine control of trophoblast growth. Cell 41: 301–312.
Granstein RD, Margolis R, Mizel SB, Sauder DN. (1985). In vivo inflammatory activity of epidermal cell-derived thymocyte activating factor and recombinant interleukin-1 in the mouse. J Clin Invest. 77: 1020–1027.
Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, Leung DW, Moffat B, Ng P, Svedersky LP. (1984). Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity. Nature. 312: 721–724.
Greaves MW. (1980). Lack of effect of typically applied epidermal growth factor (EGF) on epidermal growth in man in vivo. Clin Exp Dermatol 5: 101–103.
Green H, Kehinde O, Thomas J. (1979). Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc Natl Acad Sci USA. 76: 5665–5668.
Greenburg G, Vlodavsky I, Foidart JM, Gospodarowicz D. (1980). Conditioned medium from endothelial cell cultures can restore the normal phenotypic expression of vascular endothelium maintained in vitro in the absence of fibroblast growth factor. J Cell Physiol 103: 333–347.
Gregory H. (1975). Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature. 257: 325–327.
Grotendorst GR, Chang T, Seppa HEJ, Kleinman HK, Martin GR. (1982). Plate-let-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol 113: 261–266.
Grotendorst GR, Martin GR, Penceu D, Sodek J, Harvey AK. (1985). Stimulation of granulation tissue by platelet-derived growth factor in normal and diabetic rats. J Clin Invest. 76: 2323–2329.
Guy MW. (1975). Serum and tissue fluid lipids in rabbits experimentally infected with Trypanosoma brucei. Trans R Soc Trop Med Hyg. 69: 429–435.
Habernicht AJR, Dresel HA, Goerig M, Weber JA, Stoehr M, Glomset JA, Ross R, Schettles G. (1986). Low-density lipoprotein receptor-dependent prostaglandin synthesis in Swiss 3T3 cells stimulated by platelet-derived growth factor. Proc Natl Acad Sci USA. 83: 1344–1348.
Hackett RJ, Davis LS, Lipsky PE. (1988). Comparative effects of tumor necrosis factor-α and IL-2β on mitogen-induced T cell activation. J Immunol 140: 2639–2644.
Haigier HT, McKanna JA, Cohen S. (1979a). Direct visualization of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. J Cell Biol 81: 382–395.
Haigler HT, McKanna JA, Cohen S. (1979b). Rapid stimulation of pinocytosis in human carcinoma A431 by epidermal growth factor. J Cell Biol. 83: 82–90.
Haigler HT, Carpenter G. (1980). Production and partial characterization of an-tibody blocking epidermal growth factor: receptor interactions. Biochim Bio-phys Acta. 598: 314–325.
Hamilton RT, Nilsen-Hamilton M, Adams G. (1985). Superinduction by cy-cloheximide of mitogen induced secreted protein produced by Balb/c 3T3 cells. J Cell Physiol. 123: 201–208.
Hanazawa S, Hanaizumi C, Amano S, Hirose K, Ohmori Y, Kumegawa M, Yamaura K, Kitano S. (1988). Inductive effect of recombinant interleukin-lα and β on differentiation of macrophage-like tumor cell line P388D1. J Cell Physiol. 136: 543–546.
Härtung H-P. (1983). Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. FEBS Lett. 160: 209–212.
Härtung H-P, Parnham MJ, Winkelmann J, Engleberger W, Hadding U. (1983). Platelet-activating factor (PAF) induces the oxidative burst in macrophages. Int J Immunopharmacol. 5: 115–121.
Haskill S, Johnson C, Eierman D, Becker S, Warren K. (1988). Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. J Immunol. 140: 1690–1694.
Hazuda DJ, Lee JC, Young PR. (1988). The kinetics of interleukin-1 secretion from activated monocytes. Differences between interleukin-la and interleukin-lβ. J Biol Chem. 263: 8473–8479.
Heimark RL, Twardzik DR, Schwartz SM. (1986). Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science. 233: 1078–1080.
Heldin CH, Westermark B. (1984). Growth factors: mechanism of action and relation to oncogenes. Cell. 37: 9–20.
Hennessey PJ, Black J, Andrassy RJ. (1989). Growth factors and diabetic wound healing: epidermal growth factor and insulin. Current Surg. 46: 285–286.
Herman J, Dinarello CA, Kew MC, Rabson AR. (1985). The role of interleukin-1 in tumor NK cell interaction: correction of defective NK cell activity in cancer patients by treating target cells with IL-1. J Immunol. 135: 2882–2886.
Herschlag A, Herness IGO, Wimberly HC, Bleven ML, Diamond MP, Polan ML. (1991). The effect of interleukin-1 on adhesion formation in the rat. Am J Obstet Gynecol. 165: 771–774.
Hesse DG, Tracey KJ, Fong Y, Manoque KR, Palladino MA, Cerami A, Shires GT, Lowrey SF. (1988). Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 166: 147–153.
Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwasmatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T. (1986). Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 324: 73–76.
Hollenberg MD, Gregory H. (1976). Human urogastrone and mouse epidermal growth factor share a common receptor site in cultured human fibroblasts. Life Sci. 20: 267–274.
Honegger AM, Szapary D, Schmidt A, Lyall R, Van Obberghen E, Dull TJ, Ullrich A, Schlessinger J. (1987a). A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate protooncogene expression and DNA synthesis. Mol Cell Biol 7: 4568–4571.
Honegger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, Szapary D, Schmidt A, Ullrich A, Schlessinger J. (1987b). Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell. 51: 199–209.
Hunt TK. (1991). Wound fluid: the growth environment. In: Caldwell MD, Hunt TK, Pines E, Skover G, eds. Clinical and Experimental Approaches to Dermal and Epidermal Repair Normal and Chronic Wounds. New York: Wiley-Liss; 365: 223–230.
Hunter T, Cooper JA. (1985). Protein-tyrosine kinases. Annu Rev Biochem. 54: 879–930.
Ignotz R, Massague J. (1986). Transforming growth factor beta stimulates the expression of fibronectin and collagen and their incorporation into the extra-cellular matrix. J Biol Chem. 261: 4337–4345.
Ignotz RA, Endo T, Massague J. (1987). Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem. 262: 6443–6446.
Imamura K, Spriggs D, Kufe D. (1987). Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol. 139: 2989–2992.
Iribe H, Koga T, Kotani S, Kusumoto S, Shiba T. (1983). Stimulating effect of MDP and its adjuvant active analogues on guinea pig fibroblasts for the production of thymocyte activating factor. J Exp Med. 157: 2190–2195.
Jacob CO, McDevitt HO. (1988). Tumor necrosis factor alpha in murine au-toimmune ‘lupus’ nephritis. Nature. 331: 356–358.
Jelink DF, Lipsky PE. (1987). Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-a and interleukin-1. J Immunol. 139: 2970–2976.
Jijon AJ, Gallup DG. (1989). Assessment of epidermal growth factor in the healing process of clean full thickness skin wounds. Am J Obstet Gynecol. 161: 1658–1662.
Jiminez de Asua L, O’Farrell MK, Clinigan D, Rudland PS. (1977). Temporal sequence of hormonal interactions during the prereplicative phase of quiescent cultured 3T3 fibroblasts. Proc Natl Acad Sci USA. 74: 3845–3849.
Johnson LK, Baxter JD, Vlodavsky I, Gospodarowicz D. (1980). EGF and expression of specific genes: effect on cultured rat pituitary cells are dissociable from the mitogenic response. Proc Natl Acad Sci USA. 77: 394–398.
Johnson SE, Baglioni C. (1988). Tumor necrosis factor receptors and cytocidal activity are down-regulated by activators of protein kinase C. J Biol Chem. 263: 5686–5692.
Kaibuchi K, Tsuda T, Kikuchi A, Tanimoto T, Yamashita T, Takai Y. (1986). Possible involvement of protein kinase C and calcium ions in growth factor induced expression of c myc oncogene in Swiss 3T3 cells. J Biol Chem. 261: 1187–1192.
Kamata N, Chida K, Kimaru KR, Horikoshi M, Enomoto S, Kuroki T. (1986). Growth inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas. Cancer Res. 46: 1648–1653.
Kato Y, Gospodarowicz D. (1985). Sulfated proteoglycan synthesis by rabbit costal chondrocytes grown in the presence and absence of fibroblast growth factor. J Cell Biol. 100: 477–485.
Kaye J, Gillis S, Mizel SB, Shevach EM, Malek TA, Dinarello CA, Lachman LB, Janeway C. (1984). Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin-1 is required for the expression of receptors of interleukin-2. J Immunol. 133: 1339–1345.
Kehrl JH, Roberts AB, Luakefield LM, Jakowlew SB, Sporn MB, Fauci AS. (1986a). Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol. 137: 3855–3860.
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew SB, Alvarez-Mon MA, Derynck R, Sporn MB, Fauci AS. (1986b). Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 163: 1037–1050.
Kemp A, Mellow L, Sabbadini E. (1986). Inhibition of interleukin-1 activity by a factor in sub-mandibular glands of rats. J Immunol. 137: 2245–2251.
Keski-Oja J, Lyones RM, Moses HL. (1987). Inactive secreted form(s) of transforming growth factor-beta: activation by proteolysis. J Cell Biochem Suppl. 11 A:60.
Keski-Oja J, Blasi F, Leof EB, Moses HL. (1988). Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor beta. J Cell Biol. 106: 451–459.
Kilian PA, Kafka KL, Stern AS, Woehle D, Benjamin LR, DeChiarg TM, Gubler U, Farrar J J, Mizel SB, Lomedico PT. (1986). Interleukin-1α and interleukin-β bind to the same receptor on T cells. J Immunol. 136: 4509–4515.
Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. (1986). Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors. Ann Surg. 204: 322–330.
Knighton DR, Dowcette M, Fiegel VD, Ciresi K, Butler E, Austin L. (1988). The use of platelet derived wound healing formula in human clinical trials. In: Barbul A, Pines E, Caldwell M, Hunt TK, eds. Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Research. New York: Alan R. Liss; 266: 319–329.
Knighton DR, Ciresi K, Fiegel VD, Schumerk S, Bulter E, Kind A, Cerra F. (1990). Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet. 170: 56–60.
Koch KS, Leffert HL. (1979). Increased sodium ion influx is necessary to initiate rat hepatocyte proliferation. Cell. 18: 153–163.
Kohler N, Lipton A. (1974). Platelets as a source of fibroblast growth promoting activity. Exp Cell Res. 87: 297–301.
Krane SM, Dayer J-M, Simon LS, Bryne S. (1985). Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with inter-leukin-1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E2 and indomethacin. Coll Relat Res. 5: 99–117.
Kreuger JM, Walter J, Dinarello CA, Wolff SM, Chedid L. (1984). Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol. 246: R994 - R999.
Kriegler M, Perez C, DeFay K, Albert I, Lu SD. (1988). A novel form of TNF/ cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 53: 45–53.
Kroggel R, Martin M, Pingoud V, Dayer J-M, Resch K. (1988). Two-chain structure of interleukin-1 receptor. FEBS Lett. 229: 59–62.
Ksander GA, Ogawa Y, Chu GH, McMullin H, Rosenblatt JS, McPherson JM. (1990). Exogenous transforming growth factor-Beta2 enhances connective tissue formation and wound strength in guinea pig dermal wounds healing by secondary intent. Ann Surg. 211: 288–294.
Kull FC, Jacobs S, Cuatrecasas P. (1985). Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling and relationship to sensitivity. Proc Natl Acad Sci USA. 82: 5756–5760.
Kunkumian GK, Lafyatis R, Rennmers EF, Case JP, Kim SJ, Wilder RL. (1989). Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis. Regulation of synoviocyte proliferation, prostaglandin production and collagenase transcription. J Immunol. 143: 833–837.
Kuraoka S, Campeau JD, Rodgers KE, Nakamura RM, diZerega GS. (1992). Effects of interleukin-1 (IL-1) on postsurgical macrophage secretion of protease and protease inhibitor activities. J Surg Res. 52: 71–78.
Laato M, Ninikoshi J, Gerdin B, Lebel L. (1985). Stimulation of wound healing by epidermal growth factor: a dose-dependent effect. Ann Surg. 203: 379–381.
Laiho M, Sakesela O, Andreasen PA, Keski-Oja J. (1986). Enhanced production of extracellular deposition of the endothelial type plasminogen activator in-hibitor in cultured human lung fibroblasts by transforming growth factor beta. J Cell Biol. 103: 2403–2410.
Lawrence WT, Norton JA, Sporn B, Gorschboth C, Grotendorst GR. (1988). The reversal of an Adriamycin-induced healing impairment with chemoattractants and growth factors. Ann Surg. 203: 142–147.
Lee MD, Zentella A, Pekala PH, Cerami A. (1987). Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc Natl Acad Sci USA. 84: 2590–2594.
Leffert HL, Koch KS. (1982). Hepatocyte growth regulation by hormones in chemically defined medium: a two-signal hypothesis. Cold Spring Harbor Symposium on Cell Proliferation 9: 597–619.
Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shwely V, Nuseir N. (1987). Macrophage induced angiogenesis is mediated by tumor necrosis factor α. Nature. 329: 630–632.
Leitzel K, Cano C, Marks J, Lipton A. (1982). Failure of nerve growth factor to enhance wound healing in the hamster. J Neurosci Res. 8: 413–417.
Leizer T, Clarris BJ, Ash PE, Van Damme J, Saklatvah J, Hamilton JA. (1987). Interleukin-1 beta and interleukin-1 alpha stimulate the plasminogen activator activity and prostaglandin E2 levels of human synovial cells. Arthritis Rheum. 30: 562–566.
Leizer T, Hamilton JA. (1989). Plasminogen activator and prostaglandin E2 levels in human synovial fibroblasts. Differential stimulation by synovial activator and other cytokines. J Immunol. 143: 971–978.
Lemmon SK, Rielly MC, Thomas KA, Hoover GA, Maciag T, Bradshaw R. (1982). Bovine fibroblast growth factor: comparison of brain and pituitary preparations. J Cell Biol. 95: 162–169.
Li AKC, Koroby MJ, Schattenkerk ME, Malt RA, Young M. (1980). Nerve growth factor: acceleration of the rate of wound healing in mice. Proc Natl Acad Sci USA. 77: 4379–4381.
Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA. (1986a). Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 123: 16–24.
Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA. (1986b). Inducible interleukin-1 gene expression in vascular smooth muscle cells. J Clin Invest. 78: 1432–1438.
Libby J, Martinez R, Weber MJ. (1986c). Tyrosine phosphorylase in cells treated with transforming growth factor-beta. J Cell Physiol. 129: 159–166.
Libby P, Warner SJC, Salomon RN, Birinyi LK. (1988). Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med. 318: 1493–1498.
Like B, Massague J. (1986). The antiproliferative effect of type beta transforming growth factor occurs at a level distal from receptors for growth-activating factors. J Biol Chem. 261: 13426–13429.
Limjuco G, Galuska S, Chin J, Cameron P, Boger J, Schmidt JA. (1986). Anti-bodies of predetermined specificity to the major charged species of interleukin 1. Proc Natl Acad Sci USA. 83: 3972–3976.
Lobb R, Sasse J, Sullivan R, Shing Y, D’Amore P, Jacobs J, Klagsbrun M. (1986). Purification and characterization of heparin binding endothelial cell growth factor. J Biol Chem. 261: 1924–1928.
Lomedico PT, Gubler U, Hellman CP, Dukovich M, Giri JG, Pan YE, Collier K, Semionow R, Chua AO, Mizel SB. (1984). Cloning and expression of murine interleukin-1 in Escherichia coli. Nature. 312: 458–462.
Lovett DH, Ryan JL, Sterzel RB. (1983). A thymocyte activating factor derived from glomerular mesangial cells. J Immunol. 130: 1796–1801.
Lowenthal JW, MacDonald HR. (1986). Binding and internalizing of interleukin-1 by T cells. Direct evidence for high-and low-affinity classes of interleukin-1 receptor. J Exp Med. 164: 1060–1074.
Lowenthal JW, Cerrottini J-C, MacDonald HR. (1986). Interleukin-1-dependent induction of both interleukin-2 secretion and interleukin-2 receptor expression by thymoma cells. J Immunol. 137: 1226–1231.
Luger TA, Stadler BM, Katz SI, Oppenheim JJ. (1981). Epidermal cell (keratin-ocyte)-derived thymocyte-activating factor (ETAF). J Immunol. 127: 1493–1498.
Luger TA, Charon JA, Colot M, Micksche M, Oppenheim JJ. (1983). Chemotactic properties of partially purified human epidermal cell-derived thymocyte activating factor (ETAF) for polymorphonuclear and mononuclear cells. J Immunol. 131: 816–820.
Lynch SE, Nixon JC, Colvin RB, Antoniades HN. (1987). Role of platelet-derived growth factors in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci USA. 84: 7696–7700.
Lynch SE, Colvin RB, Antoniades HN. (1989). Growth factors in wound healing: single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest. 84: 640–646.
Lynch SE. (1991). Interactions of growth factors in tissue repair. In: Caldwell MD, Hunt TK, Pines E, Skover G, eds. Clinical and Experimental Approaches to Dermal and Epidermal Repair Normal and Chronic Wounds. New York: Wiley-Liss; 365: 341–358.
Macaig R, Cerundolo J, Isley S, Kelley PR, Forand R. (1979). An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA. 76: 5674–5679.
Madri JA, Pratt BM, Tucker AM. (1988). Phenotypic modulation of endothelial cells by transforming growth factor beta depends upon the composition and organization of the extracellular matrix. J Cell Biol. 106: 1375–1384.
March CJ, Mosley B, Larsen A, Ceretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K, Conlon PJ, Hopp TP, Cosman D. (1985). Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 315: 641–647.
Marquardt H, Todaro GJ. (1982). Human tranforming growth factor. Production by a melanoma cell line; purification and initial characterization. J Biol Chem. 257: 5220–5225.
Marquardt H, Hunkapiller HW, Hood LE, Tiuardzik DR, deLarco JE, Stephenson JR, Todaro GJ. (1983). Transforming growth factors produced by retrovirus transformed rodent fibroblasts and human melanoma cells: amino acid sequence homology with epidermal growth factor. Proc Natl Acad Sci USA. 80: 4684–4688.
Marquardt H, Hunkapiller HW, Hood LE, Todaro GJ. (1984). Rat transforming growth factor 1: structure and relation to epidermal growth factor. Science. 223: 1079–1082.
Martinet Y, Bitterman PB, Mornex J-F, Grotendorst GR, Martin GR, Crystal RG. (1986). Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature. 319: 158–160.
Massague J. (1985). Transforming growth factor-beta modulates the high affinity receptors for epidermal growth factor and transforming growth factor beta. J Cell Biol. 100: 1508–1514.
Massague J, Cheifetz S, Endo T, Nadal-Ginard B. (1986). Type-beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci USA. 83: 8206–8210.
Matrisian LM, Leroy P, Ruhlmann C, Gesnel M-C, Breathnach R. (1986). Iso-lation of the oncogene and epidermal growth factor-induced transferin gene: complex control in rat fibroblasts. Mol Cell Biol. 6: 1679–1686.
Matsushima K, Kimball ES, Durum SK, Oppenheim JJ. (1985a). Purification of human interleukin-1 from a human monocyte culture supernatants and identity of thymocyte comitogenic factor, fibroblast proliferation factor, acute phase protein inducing factor and endogenous pyrogen. Cell Immunol. 92: 290–301.
Matsushima K, Bano M, Kidwell WR, Oppenheim JJ. (1985b). Interleukin-1 increase collagen type IV production by murine mammary epithelial cells. J Immunol. 134: 904–909.
Matsushima K, Propopio A, Abe H, Scala G, Ortaldo JR, Oppenheim JJ. (1985c). Production of interleukin-1 activity by normal peripheral blood B lymphocytes. J Immunol. 135: 1132–1136.
Matsushima K, Taguchi M, Kovaks EJ, Young HA, Oppenheim JJ. (1986a). Intracellular localization of human monocyte associated interleukin-1 activity and release of biologically active IL-1 from monocytes by trypsin and plasmin. J Immunol. 136: 2883–2891.
Matsushima K, Akahoshi T, Yamada M, Furutani Y, Oppenheim JJ. (1986b). Properties of specific interleukin-1 receptor on human Epstein-Barr virus-transformed B lymphocytes: identity of the receptor for IL-la: and IL-lβ. J Immunol. 136: 4496–4501.
Maury CP, Teppo AM. (1987). Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection. J Exp Med. 166: 1132–1137.
McAdam KPWJ, Dinarello CA. (1980). Induction of serum amyloid A synthesis by human leukocytic pyrogen. In: Agawal MK, ed. Bacterial Endotoxins and Host Response. Amsterdam: Elsevier North Holland; 167–178.
McBride WH, Mason K, Withers HR, Davis C. (1989). Effect of interleukin-1, inflammation, and surgery on the incidence of adhesion formation after abdominal irradiation in mice. Cancer Res. 49: 169–173.
McCroskery PA, Arai A, Amento EP, Krane SM. (1985). Stimulation of procollagenase synthesis in human rheumatoid synovial fibroblasts by mononuclear cell factor/interleukin-1. FEBS Lett. 191: 7–12.
McGee GS, Davidson JM, Buckley A, Sommer A, Woodward SC, Aquino AM, Barbour R, Demetriou AA. (1988). Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res. 45: 145–153.
McGee GS, Broadley KN, Buckley A, Aquino A, Woodward SC, Demetriou AA, Davidson JM. (1989). Recombinant transforming growth factor beta accelerates incisional wound healing. Curr Surg. March: 103–106.
McGowan JA, Strain AJ, Bucher NLR. (1981). DNA synthesis in primary cultures of adult rat hepatocytes in a defined medium: effect of epidermal growth factor, insulin, glucagon, and cyclic AMP. J Cell Physiol. 108: 353–364.
McManus LM, Hanahan DJ, Demopoulos CA, Pinckard RN. (1980). Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGPEC), and synthetic platelet-activating factor (PAF), in the rabbit. J Immunol. 124: 2919–2924.
McManus LM, Fitzpatrick FA, Hanahan DJ, Pinckard RN. (1983). Thromboxane B2 release following acetyl glyceryl ether phosphorylcholine (AGEPC) infusion in the rabbit. Immunopharmacology. 5: 197–207.
Medcalf RL, Hamilton JA. (1986). Human synovial fibroblasts produce urokinase-type plasminogen activator. Arthritis Rheum. 29: 1397–1401.
Mescher AL, Gospodarowicz D, Moran JS. (1979). Mitogenic effect of a growth factor derived from myelin on denervated regenerates of newt forelimbs. J Exp Zool. 207: 497–503.
Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moeller A, Jacoben H, Kirchner H. (1986). Antiviral effects of recombinant tumor necrosis factor in vitro. Nature. 323: 816–819.
Michel JB, Quertermous T. (1989). Modulation of mRNA levels for urinary-and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin-1. J Immunol. 143: 890–895.
Mignatti P, Tsuboi R, Robbins E, Rifkin DB. (1989). In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol. 108: 671–682.
Mira Y, Lopez R, Joseph-Silverstein J, Rifkin DB, Ossowski L. (1986). Identification of a pituitary factor responsible for enhancement of plasminogen ac-tivator activity in breast tumor cells. Proc Natl Acad Sci USA. 83: 7780–7788.
Mizel SB, Mizel D. (1981). Purification to apparent homogeneity of murine in-terleukin-1. J Immunol. 126: 834–842.
Mondschein JS, Schömberg DW. (1981). Growth factors modulate gonadotropin receptor induction in granulosa cell cultures. Science. 211: 1179–1180.
Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. (1986). Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA. 83: 7297–7301.
Morrison RS, Sharma A, De Veillis J, Bradshaw RA. (1986). Basic fibroblast growth factor supports the survival of cerebral cortical neurons in primary culture. Proc Natl Acad Sci USA. 83: 7537–7541.
Moscatelli D, Presta M, Rifkin DB. (1986). Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and cell migration. Proc Natl Acad Sci USA. 83: 2091–2095.
Moses HL, Tucker RF, Leof EB, Coffey RJ, Halper J, Shipley GD. (1985). Type beta transforming growth factor in a growth stimulator and a growth inhibitor. Cancer Cells (Cold Spring Harbor). 3: 65–71.
Muchmore AV, Decker JM. (1985). Uromodulin a unique 85-kilodalton immunosuppressive glycoprotein from urine of pregnant women. Science. 229: 479–481.
Muchmore AV, Decker JM. (1986). An immunosuppressive 85-kilodalton glycoprotein isolated from human pregnancy urine is a high affinity ligand for recombinant interleukin-l a. J Biol Chem. 261: 13404–13407.
Mueller R, Bravo R, Burkshardt J, Curran T. (1984). Induction of c fos gene and protein by growth factors precedes activation of c myc. Nature. 312: 716–720.
Munker R, Gasson J, Ogawa M, Koeffler HP. (1986). Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature. 323: 79–82.
Muraguchi A, Kehrl JH, Butler JL, Fauci AS. (1984). Regulation of human B-cell activation, proliferation and differentiation by soluble factors. J Clin Immunol. 4: 337–347.
Murphy PA, Chesney J, Wood WB. (1974). Further purification of rabbit leukocyte pyrogen. J Lab Clin Med. 83: 310–322.
Murphy PA, Simon PL, Willoughby WF. (1980). Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte activating factors made by rabbits alveolar macrophages. J Immunol. 124: 2498–2501.
Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. (1987). Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science. 237: 1333–1336.
Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. (1986). Interleukin-1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med. 163: 1545–1547.
Nathan CF. (1987). Neutrophil activation on biological surfaces: massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest. 80: 1550–1560.
Nauts HC. (1980). The Beneficial Effects of Bacterial Infections on Host Resistance to Cancer: End Results in 449 Cases. 2nd ed. New York: Cancer Research Institute (Cancer Research Institute Monograph); vol 8.
Nawroth PP, Stern DM. (1986). Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 163: 740–745.
Nawroth PP, Handley DA, Esmon CT, Stern DM. (1986a). Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anti-coagulant activity. Proc Natl Acad Sci USA. 83: 3460–3464.
Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. (1986b). Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J Exp Med. 163: 1363–1375.
Neufeld G, Gospodarowicz D. (1985). The identification and partial characterization of the fibroblast growth factor receptor of baby hamster kidney cells. J Biol Chem. 260: 13860–13868.
Neufeld G, Gospodarowicz D. (1986). Basic and acidic fibroblast growth factor interact with the same cell surface receptor. J Biol Chem. 261: 5631–5637.
Newton RC. (1985). Effect of interferon on the induction of human monocyte secretion of interleukin-1 activity. Immunology. 56: 441–449.
Niall M, Ryan GB, O’Brien BM. (1982). The effect of epidermal growth factor on wound healing in mice. J Surg Res. 33: 164–169.
Nieuwkoop PD. (1969). The formation of mesoderm in Urodelean amphibians. I. Induction by the ectoderm. Wilhelm Roux’ Arch Entw Mech Org. 162: 341–373.
Nilsen-Hamilton M, Shapiro JM, Massoglia SL, Hamilton RT. (1980). Selective stimulation by mitogens of incorporation of S-methionine into a family of proteins released into the medium by 3T3 cells. Cell. 20: 19–28.
Nilsen-Hamilton M, Hamilton RT, Allen WR, Massoglia S. (1981). Stimulation of the release of two glycoproteins from mouse 3T3 cells by growth factors and by agents that increase intralysosomal pH. Biochem Biophys Res Commun. 101: 411–417.
O’Malley WE, Achinstein B, Shear MJ. (1962). Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide and induce tolerance. J Nat Cancer Inst. 29: 1169–1175.
Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH. (1987). Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 50: 555–563.
Olwin BB, Hauschka SD. (1986). Identification of the fibroblast growth factor receptor of Swiss 3T3 cells and mouse skeletal myoblasts. Biochemistry. 25: 3487–3492.
Panaretto BA, Leish Z, Moore GP, Robertson DM J. (1984). Inhibition of DNA synthesis in dermal tissue of merino sheep treated with depilatory doses of mouse epidermal growth factor. J Endocr. 100: 25–31.
Parfett CLJ, Hamilton RT, Howell BW, Edwards DR, Nilsen-Hamilton M, Denhardt DT. (1985). Characterization of a cDNA clone encoding murine mitogen regulated protein: regulation of mRNA levels in mortal and immortal cell lines. Mol Cell Biol. 5: 3289–3292.
Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwall BB, Goeddel DY. (1984). Human tumor necrosis factor-precursor, structure, expression and homology to lymphotoxin. Nature. 312: 724–729.
Pennica D, Hayflick JS, Bringham TS, Palladino MA, Goeddal DV. (1985). Cloning and expression in E. coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA. 82: 6060–6064.
Perlmutter D, Goldberger G, Dinarello CA, Mizel SB, Colten HR. (1986a). Regulation of class II major histocompatability complex gene products by inter-leukin-1. Science. 232: 850–852.
Perlmutter D, Dinarello CA, Punsal P, Colten HR. (1986b). Cachectin/tumor necrosis factor regulates hepatic acute phase gene expression. J Clin Invest. 78: 1349–1354.
Pessa ME, Bland KI, Sitren HS, Miller GJ, Copeland EM III. (1985). Improved wound healing in tumor-bearing rats treated with perioperative synthetic human growth hormone. Surg Forum. 36: 6–8.
Pierce GF, Mustoe TA, Deuel TF. (1988a). Transforming growth factor β induces increased directed cellular migration and tissue repair in rats. In: Barbul A, Pines E, Caldwell M, Hunt TK, eds. Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Research. New York: Alan R. Liss; 266: 93–102.
Pierce GF, Mustoe TA, Senior RM, Reed J, Griffin GL, Thomason A, Deuel TF. (1988b). In vivo incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins. J Exp Med. 167: 974–987.
Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, Deuel TF. (1989a). Platelet-derived growth factor and transforming growth factor-β enhance tissue repair activities by unique mechanisms. J Cell Biol. 109: 429–440.
Pierce GF, Mustoe TA, Lingelbach J, Masakowski V, Gramates P, Deuel TF. (1989b). Transforming growth factor ß reverses the glucocorticoid-induced wound healing deficit in rats and is regulated by platelet-derived growth factor in macrophages. Proc Natl Acad Sci USA. USA 86: 2229–2233.
Pierce GF, Yanagihara D, Thomason A, Fox GM. (1990). PDGF, TGF-β and basic FGF differentially induce extracellular matrix, neovessel formation and re-epithelialization in lapine excisional wounds. FASEB J. 4 (3): A624.
Piguet PF, Grau GE, Allet B, Vassalli P. (1987). Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med. 166: 1280–1289.
Pinckard RN, McManus LM, Demopoulos CA, Halonen M, Clark PO, Shaw JO, Kniker WT, Hanahan DJ. (1980). Molecular pathobiology of acetyl glyceryl ether phosphorylcholine (AGEPC): Evidence for the structural identity with platelet-activating factor (PAF). J Reticuloendothel Soc. 28: 95s–103s.
Pincus SH, Whitcomb EA, Dinarello CA. (1986). Interaction of interleukin-1 and TPA in modulation of eosinophil function. J Immunol. 137: 3509–3514.
Pober JS, Gimbrone MA, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. (1986a). Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor and immune interferon. J Immunol. 137: 1893–1896.
Pober JS, Bevilacqua MP, Mendrick DL, Lapierre PA, Fiers W, Gimbrone MA. (1986b). Two distinct monokines, interleukin-1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 136: 1680–1683.
Pober JS. (1987). Effects of tumor necrosis factor and related cytokines on vascular endothelial cells. In: Bock G, Marsh J, eds. Tumor Necrosis Factor and Related Cytokines. Ciba Foundation Symposium 131. Chichester: John Wiley; 88–108.
Pohlman TH, Stanness KA, Beatty PG, Ochs HE, Harlan JM. (1986). An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin-1, and tumor necrosis factor-a increases neutrophil adherence by a CDwl 8-dependent mechanism. J Immunol 136: 4548–4553.
Postlethwaite AE, Lachman LB, Mainardi CL, Kang AH. (1983). Interleukin-1 stimulation of collagenase production by cultured fibroblasts. J Exp Med. 157: 801–806.
Prakash A, Pandit PN, Sharma LK. (1974). Studies in wound healing in experimental diabetes. Int Surg. 59 (l): 25–36.
Raghow R, Postlethwaite AK, Keski-Oja J, Moses HL, Kang AH. (1987). Trans-forming growth factor-beta increases steady state levels of type I procollagen and fibronectin mRNAs post transcriptionally in cultured human dermal fibroblasts. J Clin Invest. 79: 1285–1288.
Ramadori G, Sipes JD, Dinarello CA, Mizel SB, Colter HR. (1985). Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin-1 and purified human IL-1. J Exp Med. 162: 930–942.
Richman RA, Claus TH, Pilkis SJ, Friedman DL. (1976). Hormonal stimulation of DNA synthesis in primary cultures of adult rat hepatocytes. Proc Natl Acad Sci USA. 60: 1620–1624.
Risau W. (1986). Developing brain produces an angiogenesis factor. Proc Natl Acad Sci USA. 83: 3855–3859.
Roberts AB, Anzano MA, Meyers CA, Sporn MB. (1983). Purification and properties of a type-β transforming growth factor from bovine kidney. Biochemistry. 22: 5692–5698.
Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. (1985). Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA. 82: 119–123.
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield PM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. (1986). Transforming growth factor type-beta; rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 83: 4167–4171.
Roberts AB, Sporn MB. (1988a). Transforming growth factor beta: new chemical forms and new biological roles. Biofactors. 1: 89–93.
Roberts, AB, Sporn MB. (1988b). Transforming growth factor beta. Adv Cancer Res. 51: 107–145.
Roberts NJ, Prill AH, Mann TN. (1986). Interleukin-1 and interleukin-1 inhibitor production by human macrophages exposed to influenza virus or respiratory syncytial virus. J Exp Med. 163: 511–519.
Robey PG, Young MF, Handers KC, Roche NS, Kondaiah P, Reddi AH, Termine JD, Sporn MB, Roberts AB. (1987). Osteoblasts synthesize and respond to TGF-beta in vitro. J Cell Biol. 105: 457–463.
Rodgers BC, Scott DM, Mundin J, Sissons JGP. (1985). Monocyte-derived inhibitor of interleukin-1 induced by human cytomegalovirus. J Virol. 55: 527–532.
Rodgers KE, diZerega GS. Modulation of peritoneal re-epithelialization by post-surgical macrophages. J Surg Res. (in press). Roger PP, Dumont JE. (1982). Epidermal growth factor controls the proliferation and the expression of differentiation in canine thyroid cells in primary culture. FEBS Lett. 144:209–212.
Rosenwasser LJ, Dinarello CA, Rosenthal A. (1979). Adherent cell function in murine T-lymphocyte recognition by human leukocytic pyrogen. J Exp Med. 150: 709–714.
RosoffPM, Savage N, Dinarello CA. (1988). Interleukin-1 stimulates diacylglycerol production by T lymphocytes by a novel mechanism. Cell. 54: 73–81.
Ross R, Glomset JA, Kariya B, Harker L. (1974). A platelet-derived serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA. 71: 1207–1210.
Ross R. (1986). The pathogenesis of atherosclerosis: an update. N Engl J Med. 314: 488–500.
Ross R, Raines EW, Bowen-Pope DF. (1986). The biology of platelet-derived growth factor. Cell. 46: 155–169.
Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A. (1985). Interleukin-1 induces prostacyclin in vascular cells. Science. 229: 1174–1176.
Rouzer CA, Cerami A. (1980). Hypertriglyceridemia associated with Trypanosoma brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol. 2: 31–38.
Rozengurt E, Heppel LA. (1975). Serum rapidly stimulates ouabain-sensitive 86Rb+ influx in quiescent 3T3 cells. Proc Natl Acad Sci USA. 72: 4492–4495.
Ruggiero V, Tavernier J, Fiers W, Baglioni C. (1986). Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J Immunol. 136: 2445–2450.
Ruggiero V, Latham K, Baglioni C. (1987). Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol. 138: 2711–2717.
Saklatvala J, Sarsfield SJ, Townsend Y. (1985). Pig interleukin-1: purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation and fever. J Exp Med. 162: 1208–1222.
Saklatvala J. (1986). Tumor necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 322: 547–549.
Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. (1987). Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science. 238: 522–524.
Sauder DN, Dinarello CA, Morhenn VB. (1984a). Langerhans cell production of interleukin-1. J Invest Dermatol. 82: 605–607.
Sauder DN, Mounessa NL, Katz SI, Dinarello CA, Gallin JI. (1984b). Chemo-tactic cytokines. The role of leukocytic pyrogen and epidermal cell thymocyte activating factor in neutrophil chemotaxis. J Immunol. 132: 828–832.
Sayers TJ, Wiltrout TA, Bull CA, Denn AC, Pilaro AM, Lokesh B. (1988). Effects of cytokines on polymorphonuclear neutrophil infiltration in the mouse. Prostaglandin-and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor. J Immunol. 141: 1670–1677.
Schlessinger J, Schechter Y, Willingham MC, Pastan I. (1978). Direct visualization of binding, aggregation and internalization of insulin and epidermal growth factor on living fibroblast cells. Proc Natl Acad Sci USA. 75: 2659–2663.
Schlessinger J, Geiger B. (1981). Epidermal growth factor induces redistribution of actin and actinin in human epidermal carcinoma cells. Exp Cell Res. 134: 273–279.
Schlessinger J. (1987). Allosteric regulation of the epidermal growth factor receptor kinase. J Cell Biol. 103: 2067–2072.
Schmidt J A, Mizel SB, Cohen D, Green I. (1982). Interleukin-1, a potential regulator of fibroblast proliferation. J Immunol. 128: 2177–2182.
Schnyder J, Payne T, Dinarello CA. (1987). Human monocyte or recombinant interleukin-1s are specific for the secretion of a metalloproteinase from chondrocytes. J Immunol. 138: 496–503.
Schonbrunn A, KrashoffM, Westerdorf JM, Tashyan AH. (1980). EGF and TRH act similarly on a clonal pituitary cell strain. J Cell Biol. 85: 786–797.
Schwartz T, Urbanska A, Gschnait F, Luger TA. (1987). UV-irradiated epidermal cells produce a specific inhibitor of interleukin-1 activity. J Immunol. 138: 1457–1463.
Seckinger P, Lowenthal JW, Williamson K, Dayer J-M, MacDonald HR. (1987). An urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol. 139: 1546–1549.
Seifert RA, Hart CE, Phillips PE, Forstran JW, Ross R, Murray MJ, Bowen-Pope DF. (1989). Two different subunits associate to create isoform-specific PDGF receptors. J Biol Chem. 264: 8771–8778.
Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA. (1985). Purification and characterization of two cartilage-inducing factors from bovine de-mineralized bone. Proc Natl Acad Sci USA. 82: 2267–2271.
Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA. (1985). Activation of human polymorphonuclear neutrophil functions by interferon-7 and tumor necrosis factors. J Immunol. 135: 2069–2073.
Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, Hanahan DJ. (1981). Activation of human neutrophils with 1-O-hexadecyl/octadecyL-2-acetyl-sn-gly-ceryL-3-phosphorylcholine (platelet-activating factor). J Immunol. 127: 1250–1255.
Shear MJ. (1944). Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J Nat Cancer Inst. 4: 461–476.
Shechter Y, Hernaez L, Cuatrecasas P. (1978). Epidermal growth factor: biological activity requires persistent occupation of high-affinity cell surface receptors. Proc Natl Acad Sci USA. 75: 5788–5791.
Shimokado K, Raines EW, Madres DK, Barrett TB, Benditt EP, Ross R. (1985). A significant part of macrophage-derived growth factor consists of at least two forms of PDGF. Cell. 43: 277–286.
Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB. (1985). Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature. 313: 803–806.
Simonian MH, Hornsby PJ, Ill CR, O’Hare MJ, Gill GN. (1979). Characterization of cultured bovine adrenal cortical and derived clonal lines: regulation of steroidogenesis and culture life span. Endocrinology. 105: 99–108.
Sims JE, March CJ, Cosman D, Widmar MB, MacDonald HR, McMahan CJ, Grubin CE, Wignall JM, Jackson JL, Call SM. (1988). cDNA expression cloning of the IL-1 receptor a member of the immunoglobulin super family. Science. 241: 585–589.
Slack JMW, Darlington BF, Heath HK, Godsave SF. (1987). Heparin binding growth factors as agents of mesoderm induction in early xenopus embryo. Nature. 326: 197–200.
Smith JC, Dale L, Slack JMW. (1985). Cell lineage and region-specific markers in the analysis of inductive interactions. J Embryol Exp Morphol. 89 (suppl): 317–331.
Smith RJ, Bowman BJ, Iden SS. (1984). Stimulation of the human neutrophil superoxide anion-generating system with l-O-hexadecyl/octadecyL-2-acetyl-sn-glyceryL-3-phosphorylcholine. Biochem Pharmacol. 33: 973–978.
Smith RJ, Bowman BJ, Speziale SC. (1986). Interleukin-1 stimulates granule exocytosis from human neutrophils. Int J Immunopharmacol. 8: 33–40.
Solis-Herruzo JA, Brenner DA, Chojkier M. (1988). Tumor necrosis factor-d inhibits collagen gene transcription and collagen synthesis in cultured human fibroblast. J Biol Chem. 263: 5841–5845.
Sporn MS, Roberts PB, Shull JH, Smith JM, Ward JM, Sodek J. (1983). Poly-peptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science. 219: 1329–1331.
Sprugel KH, Greenhalgh DG, Murray MJ, Ross R. (1991). Platelet-derived growth factor and impaired wound healing. In: Caldwell MD, Hunt TK, Pines E, Skover G. eds. Clinical and Experimental Approaches to Dermal and Epidermal Repair Normal and Chronic Wounds. New York: Wiley-Liss; 365: 325–340.
Steed D, Goslen B, Hambley R, Abell E, Hebda P, Webster M. (1991). Clinical trials with purified platelet releasate. In: Caldwell MD, Hunt TK, Pines E, Skover G, eds. Clinical and Experimental Approaches to Dermal and Epidermal Repair Normal and Chronic Wounds. New York: Wiley-Liss; 365: 103–114.
Steenfos HH, Hunt TK, Scheuenstuhl H, Goodson WH. (1989). Selective effects of tumor necrosis factor-alpha on wound healing in rats. Surgery. 106: 171–176.
Stephenson ML, Golding MB, Burkhead JR, Krane SM, Rhamsdorf HJ, Angel P. (1987). Stimulation of procollagenase synthesis parallels increases in cellular procollagenase mRNA in human articular chondrocytes exposed to recombinant interleukin-1 or phorbol ester. Biochem Biophys Res Commun. 144: 583–590.
Stiles CD, Capne GT, Scher CD, Antoniades HM, Van Wyk JJ, Pledger WJ. (1979). Dual control of cell growth by somatomedins and “competence factors.” Proc Natl Acad Sci USA. 76: 1279–1283.
Stiles CD. (1983). The molecular biology of platelet-derived growth factor. Cell. 33: 653–655.
Subramanian N, Bray MA. (1987). Interleukin-1 releases histamine from human basophils and mast cells in vitro. J Immunol. 138: 271–275.
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM. (1985). Recombinant tumor necrosis factor alpha: Effects on proliferation of normal and transformed cells in vitro. Science. 230: 943–945.
Sun TT, Green H. (1977). Cultured epithelial cells of cornea, conjunctiva and skin: absence of marked intrinsic divergence of their differentiated states. Nature. 269: 489–492.
Sundeil HW, Senenius RS, Barthe P, Friedman Z, Kanarek KS, Escobedo MB, Orth DN, Stahlman MT. (1975). The effect of EGF on fetal lamb lung maturation. Pediatr Res. 9:371. Sundell HW, Gray ME, Serenius RS, Scobedo MBE, Stahlman MT. (1980). Maturation in fetal lamb. Am J Pathol. 10: 707–726.
Takehara K, LeRoy EC, Grotendorst GR. (1987). TGF-beta inhibition of endothelial cell proliferation: alteration of EGF binding and EGF-induced growth-regulatory (competence) give expression. Cell. 49: 415–422.
Takeda K, Iwamoto S, Sugimoto H, Takuma T, Kawatani N, Noda M, Masaki A, Morise H, Arimura H, Konro K. (1986). Identity of differentiation inducing factor and tumor necrosis factor. Nature. 323: 338–340.
Thornton JW, Hess CA, Cassingham V, Bartlett RH. (1981). Epidermal growth factor in the healing of second degree burns. A controlled animal study. Burns 8: 156–160.
Tiku K, Tiku ML, Liu S, Skosey JL. (1986). Normal human neutrophils are a source of specific interleukin-1 inhibitor. J Immunol. 136: 3686–3692.
Togari A, Dickens G, Huzuya H, GuroffG. (1985). The effect of fibroblast growth factor on PC-12 cell. J Neurosci. 5: 307–316.
Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM. (1987). A macro-phage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science. 229: 867–869.
Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolfe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD. (1986). Shock and tissue injury induced by recombinant human cachectin. Science. 234: 470–474.
Tracey KJ, Lowry SF, Fahey TJ III, Albert JD, Fong Y, Hesse D, Bieutler B, Manoque KR, Calvano S, Wei H. (1987). Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 164: 415–422.
Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A. (1988). Cachectin/tumor necrosis factor in-duces cachexia, anemia and inflammation. J Exp Med. 167: 1211–1227.
Trinchieri G, Kobayashi M, Rosen M, Louden R, Murphy M, Perussia B. (1986). Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med. 164: 1206–1225.
Tseng S, Savion N, Stern R, Gospodarowicz D. (1982). Fibroblast growth factor modulates synthesis of collagen in cultured vascular endothelial cells. Eur J Biochem 122: 355–360.
Tsuda T, Kaibuchi K, Kawahara Y, Fukuzaki H, Takai Y. (1985). Induction of protein kinase C and calcium ion mobilization by fibroblast growth factor in Swiss 3T3 cells. FEBS Lett. 191: 205–210.
Tsujimoto M, Kip YK, Vilcek J. (1985). Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci USA. 82: 7626–7630.
Tucker RF, Shipley GD, Moses HL, Holley RW. (1985). Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science. 226: 705–707.
Ullrich A, Coussens L, Haylick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Liberman TA, Schlessinger J, Downward J, Bye J, Whittle N, Waterfield MD, Seeburg PH. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309: 418–425.
Urdal DL, Call SM, Jackson JL, Dower SK. (1988). Affinity purification and chemical analysis of the interleukin-1 receptor. J Biol Chem. 263: 2870–2875.
Ushiro H, Cohen S. (1980). Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membrane. J Biol Chem. 255: 8363–8365.
Van Damme J, De Ley M, Opdenakker G, Biliau A, De Somer P. (1985). Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1. Nature. 314: 266–268.
Van Damme J, Billiau A. (1987). Interferon betA-2 and plasmacytoma growth factor are identical to B-cell stimulating factor 2. J Exp Med. 163: 145–168.
Vilcek J, Palombell VJ, Henryksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M. (1986). Fibroblast growth enhancing activity of tumor ne-crosis factor and its relationship to other polypeptide growth factors. J Exp Med. 163: 632–642.
Vlodavsky I, Gospodarowicz D. (1979). Structural and functional alterations in the surface of vascular endothelial cells associated with the formation of a confluent cell monolayer and with the withdrawal of fibroblast growth factor. J Supramol Struct. 12: 73–114.
Vlodavsky I, Johnson LK, Greenburg G, Gospodarowicz D. (1979). Vascular endothelial cells maintained in the absence of fibroblast growth factor undergo structural and functional alterations that are incompatible with their in vivo differentiated properties. J Cell Biol. 83: 468–486.
Vuk-Pavlovic S, Svingen P, Vroman B, Kovach JS. (1987). inhibition of colony formation and DNA degradation by tumor necrosis factor-alpha in human epithelial tumors. Proc Am Assoc Cancer Res. 28: 400–405.
Vuk-Pavlovic S, Kovach JS. (1989). Recycling of tumor necrosis factor-a receptor in MCF-7 cells. FASEB J. 3: 2633–2640.
Wagner JA, D’Amore P. (1986). Neunte outgrowth induced by an endothelial cell mitogen isolated from retina. J Cell Biol. 103: 1363–1367.
Wahl SM, Hunt DA, Wakefield LM, McCartney-Frances N, Wahl LM, Roberts AB, Sporn MB. (1987). Transforming growth factor beta (TGF-beta) induces monocyte Chemotaxis and growth factor production. Proc Natl Acad Sci USA. 84: 5788–5792.
Wahl SM, Hunt DA, Wong HL, Dougherty S, McCartney-Francis N, Wahle LM. (1988a). Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1 dependent lymphocyte proliferation. J Immunol. 140: 3026–3032.
Wahl SM, Hunt DA, Bansal G, McCartney-Francis N, Ellingsworth L, Allan JB. (1988b). Bacterial cell wall induced immunosuppression. Role of TGF-β. J Exp Med. 168: 1403–1417.
Wahl SM, McCartney-Francis N, Mergenhagen SE. (1989). Inflammatory and immunomodulatory roles of TGF-β. Immunol Today. 10: 258–261.
Wakefield LM, Smith MDM, Masui T, Harris CC, Sporn MB. (1987). Distribution and modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol. 105: 965–975.
Walicke P, Cowan M, Ueno N, Baird B, Guillemin R. (1986). Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension. Proc Natl Acad Sci USA. 83: 3012–3016.
Walsh LJ, Lander PE, Seymour GJ, Powell RN. (1987). Isolation and purification of 1LS, an interleukin-1 inhibitor produced by human gingival epithelial cells. Clin Exp Immunol. 68: 366–374.
Warren RS, Donner DB, Starnes HF, Brennan MF. (1987). Modulation of endogenous hormone action by recombinant human tumor necrosis factor. Proc Natl Acad Sci USA. 84: 8619–8622.
Waterfield MD, Scrace GT, Whittle N, Stroobant P, Johnsson A, Bornert JM, Staub A. (1985). Platelet-derived growth factor is structurally related to the putative transforming protein P 28 sis of simian sarcoma virus. Nature. 304: 35–39.
Westermark B, Heldin C-H, Ek B, Westermark K. (1983). Biochemistry and biology of platelet-derived growth factor. In: Guroff G, ed. Growth and Maturation Factors. Philadelphia: Wiley; 73–92.
Westermark K, Karlsson FA, Westermark B. (1983). Epidermal growth factor modulates thyroid growth and function in culture. Endocrinology. 112: 1680–1686.
Williams RS, Rossi AM, Chegini N, Shultz G. (1992). Effect of transforming growth factor beta on postoperative adhesion formation and intact peritoneum. J Surg Res 52 (l): 65–70.
Williamson BD, Carswell EA, Rubin BY, Prendergast YS, Old LJ. (1983). Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA. 80: 5397–5401.
Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. (1987). Transforming growth factor beta (TGF-β) is a chemoattractant for monocytes and induces their expression of angiogenic activity. J Cell Biol. 105: 163a.
Wood DD, Bayne EK, Goldring MB, Gowen M, Hamerman D, Humes JL, Ihrie EJ, Lipsky PE, Staruch MJ. (1985). The four biochemically distinct species of human interleukin-1 exhibit similar biologic activities. J Immunol. 134: 895–903.
Wrann M, Fox CF, Ross R. (1980). Modulation of epidermal growth factor receptors on 3T3 cells by platelet derived growth factor. Science. 210: 1363–1365.
Yarden Y, Ullrich A. (1988). Molecular analysis of signal transduction by growth factors. Biochemistry. 27: 3113–3119.
Yasaka T, Boxer LA, Baehner RL. (1982). Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). J Immunol. 128: 1939–1944.
Zucali JR, Dinarello CA, Obion DJ, Gross MA, Anderson I, Werner RS. (1986). Interleukin-1 stimulates fibroblasts to produce granulocyte-macrophage colony stimulating activity and prostaglandin-E2. J Clin Invest. 77: 1857–1863.
Zucali JR, Elfenbein GJ, Barth KC, Dinarello CA. (1987). Effects of human in-terleukin-1 and human tumor necrosis factor on human T lymphocyte colony formation. J Clin Invest. 80: 772–777.
Zullo JN, Cochran BH, Huang A, Stiles CD. (1985). Platelet-derived growth factor and double-stranded ribonucleic acids stimulate expression of the same genes in 3T3 cells. Cell. 43: 793–800
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin New York, Inc.
About this chapter
Cite this chapter
diZerega, G.S., Rodgers, K.E. (1992). Growth Factors. In: The Peritoneum. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-9235-4_3
Download citation
DOI: https://doi.org/10.1007/978-1-4613-9235-4_3
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4613-9237-8
Online ISBN: 978-1-4613-9235-4
eBook Packages: Springer Book Archive